bioRxiv / medRxiv
open access
Cost-effectiveness of a package to ensure safe prescription of 7-day high-dose primaquine for the radical cure of Plasmodium vivax in Indonesia
The radical cure of Plasmodium vivax requires treatment of the dormant liver stages with either primaquine or tafenoquine, but widespread implementation of this policy is constrained by the risk of severe hemolysis in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. A revised case-
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Study to Assess the Incidence of Hemolysis, Safety, and Efficacy of Tafenoquine (SB-252263, WR238605) Versus Primaquine in Subjects With Plasmodium Vivax Malaria#1310076
- G6PD Assessment Before Primaquine for Radical Treatment of Vivax Malaria#876438
- Postpartum Primaquine in Breast Milk#874227
- Primaquine for Vivax Malaria in G6PD Intermediate and Deficient Cases.#992010
- Eight Week Primaquine Regimen for the Treatment of Vivax Malaria#851724
Record · ID 1436332
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive